Seb Montoya’s Post

While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money. In fact, both Forbion and BioGeneration Ventures announced their largest biopharma funds to date earlier this year. Meanwhile, Germany’s High-Tech Gründerfonds, which invests across life sciences, digital tech and high tech, also saw its largest raise at almost half a billion euros. So, despite an icy IPO market, is investor interest in European biotechs holding up? https://buff.ly/3Qpbo7M #MBExec #ExecutiveSearch #LifeSciences #Healthcare #WereProYou #Leadership #ExecSearch #Recruiting

Today I was interviewed by Trends Kanaal Z. Belgium does not escape the current slowdown in fundraising for venture capital. VC growth companies raised only 768 million € in 2023, compared to 1,5 billion € in 2022. Our industry faces challenging times as investors ask for profitability instead of growth at all cost. Although far less than in 2022, the amount of 768 million € is still in line with the amounts raised in 2018 and 2019. And on a positive note: the Belgian biotech sector continues to perform strongly thanks to excellent expertise, local funding and long term tax stability. #venturecapital #growth #biotech #lifesciences BVA | Belgian Venture Capital & Private Equity Association

ALPS Global Holding Berhad stands at the forefront of the Bio-Tech industry in Southeast Asia, poised for a significant milestone as it prepares for a NASDAQ listing in the coming months, unfurling the banner of a unicorn valuation. Spearheading the investment arm is the esteemed Datuk Mohd Razef (centre in photo). Today marks a pivotal moment for Vista Capital as we proudly announce our role as one of the select entities entrusted to facilitate the exclusive Pre-IPO fundraising campaign for ALPS. For those unacquainted with this groundbreaking bio-tech enterprise, their mission is nothing short of transformative – to elevate and prolong human life through exceptional Anti-Aging Care & Wellness Services. In pursuit of its vision for a rejuvenated humanity, ALPS, a fully-integrated biotechnology research, medical, and wellness services powerhouse, is committed to a dual-pronged strategy. This involves enhancing the overall quality of life and extending the average lifespan by delivering cutting-edge anti-aging care and wellness services at the forefront of technological innovation. The imminent weeks mark the commencement of our campaign, and we eagerly anticipate collaborating with cooperative entities, as well as private equity and venture capital firms, both domestically & internationally. #VistaCApital #BioTechInnovation #PreIPO #FutureWellness #Unicorn 𝐕𝐢𝐬𝐭𝐚 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 “𝑊ℎ𝑒𝑟𝑒 𝑉𝑖𝑠𝑖𝑜𝑛 𝑀𝑒𝑒𝑡𝑠 𝑉𝑎𝑙𝑢𝑒”

🔍 A first glance at our regular EMEA Life Sciences insights to come for 2024! 🔎 Looking forward to studying how these fundings translate into the upcoming European life sciences real estate market. #LifeSciences #JLL #RealEstate

Up next at #InnovationDublin24 is the “Early Stage Investing” Panel Session, moderated by Hughes TJ, Senior Development Adviser Lifesciences, Enterprise Ireland.   ●     Paul Gilson, Entrepreneur and Angel Investor ●     Niall McEvoy, Venture Partner, Elkstone Ventures ●     Will Wyman, European Investment Bank (EIB) ●     Michelle Tierney, CSO & Co-Founder, SymPhysis Medical SymPhysis Medical is a prime example of benefitting from non-dilutive awards available in Ireland and Europe, bridging it to an external seed-plus funding round and Series A readiness. Start-ups may apply through the EIC accelerator for a maximum of €2.5 million. Current challenge: M&A is down, there are very few small, bolt-on acquisitions. This has caused investors to keep funds for the support of existing portfolio companies, creating challenges for new companies trying to raise Series A rounds.   Be mindful of ESG (sustainability and ethical business practice issues), which is top of mind for investors and buyers alike.   Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

Health-focused #VC fundraising, early-stage investment deals, and promising new technologies are generating optimism for the #healthcare innovation ecosystem. ▪ $19B raised by U.S. VC firms for health-focused funds. ▪ 42% of healthcare deals were spoon-fed. The proportion of deals involving later-stage companies valued at more than $20M raising $15M or less is on the rise. ▪ 19 biopharma IPOs in 2023. Read the latest #SVBHealthcare report for a full update on how the sector has responded to a challenging macro environment.

ALPS Global Holding Berhad stands at the forefront of the Bio-Tech industry in Southeast Asia, poised for a significant milestone as it prepares for a NASDAQ listing in the coming months, unfurling the banner of a unicorn valuation. Spearheading the investment arm is the esteemed Datuk Mohd Razef (centre in photo). Today marks a pivotal moment for Vista Capital as we proudly announce our role as one of the select entities entrusted to facilitate the exclusive Pre-IPO fundraising campaign for ALPS Global Holding Berhad. For those unacquainted with this groundbreaking bio-tech enterprise, their mission is nothing short of transformative – to elevate and prolong human life through exceptional Anti-Aging Care & Wellness Services. In pursuit of its vision for a rejuvenated humanity, ALPS, a fully-integrated biotechnology research, medical, and wellness services powerhouse, is committed to a dual-pronged strategy. This involves enhancing the overall quality of life and extending the average lifespan by delivering cutting-edge anti-aging care and wellness services at the forefront of technological innovation. The imminent weeks mark the commencement of our campaign, and we eagerly anticipate collaborating with cooperative entities, as well as private equity and venture capital firms, both domestically & internationally. #VistaCApital #BioTechInnovation #PreIPO #FutureWellness #Unicorn 𝐕𝐢𝐬𝐭𝐚 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 “𝑊ℎ𝑒𝑟𝑒 𝑉𝑖𝑠𝑖𝑜𝑛 𝑀𝑒𝑒𝑡𝑠 𝑉𝑎𝑙𝑢𝑒”

🌟 NLC's 2023 Recap: Empowering Healthcare Innovation 🌟 Despite challenges in the venture capital landscape, marked by an overall decline in funding, NLC has continued on an upward journey in 2023 building new ventures and attracting investments. 🚀 Here are some of our key highlights in 2023👇 🌍 Built over 20 ventures addressing critical healthcare challenges 🤝Expanded investor network: Attracted over 100 private investors from 16 different countries 📈 75 investment transactions finalized 🎉 Closed the first (€20M) tranche of the new NLC Health Impact fund 💰 Our ventures raised over € 35 million  🥇 NLC was named the number 1 most active early-stage healthcare investor in Europe by Financial Times' Sifted 🏆 Looking Forward to 2024: As we enter the new year, NLC is poised to explore new horizons, invest in transformative ventures, and cultivate strategic partnerships for a lasting impact on global health. #innovation #nlc #healthtech #venturecapital #impactinvesting

The winner of the Newcomer of The Year category at the European VC Awards is Amino Collective! 🥇 Amino Collective is an institutional venture capital firm investing in health and bio companies at the seed stage. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in biology, biotech, health tech, science, digital health, life science, and synthetic biology. Here's why they impressed the judges: 👉 Impressive fundraising: Secured a massive €40M in lightning speed, attracting top-tier investors. 👉 Stellar initial investments: Their early bets promise to disrupt entire industries. 👉 €150M follow-on funding: Investors A16Z, Index Ventures, and Accel are betting on Amino Collective's future. The Newcomer of the Year award celebrates rising managers who bring fresh perspectives to European ventures. This category has been supported by Floww, a solution that simplifies venture capital fund management, with FlowwFunds, a full funds management solution. #VentureCapital #StartupFunding #Fundraising #EuropeanVCAwards #Europe

** 𝗔𝗹𝗹 𝗮𝗯𝗼𝗮𝗿𝗱 𝘁𝗵𝗲 𝗙𝗹𝗮𝗴𝘀𝗵𝗶𝗽🚀!!!** Since launching in 2000, Flagship Pioneering have successfully led over 100+ scientific ventures, amounting to an impressive $75 billion in aggregate value. With this recent $3.6 billion round of fund influx, since 2021, capital raised by Flagship now totals $6.4 billion 💰 Flagship will use their increased capital to fuel the growth of 25 new breakthrough companies in human health, sustainability, and artificial intelligence 🙌🏽 With global expansion plans in mind, let’s hope this leads to the creation of much needed new employment opportunities 🙏🏽 🔗to full Prnewswire article below #venturecapital #lifescienceinnovation #funding